fda warning glp-1 november 2025 Diabetes advocacy group discourages use of compounded drugs FDA warns consumers not to

Three things must be true before switching to this reduced frequency

Compared to other anti-obesity medications (e.g., dulaglutide and semaglutide) administered over the same duration, tirzepatide demonstrated a superior reduction in body fat compartments, including total fat mass, VAT, and waist circumference [63]

Common Side Effects (Mild) Injection site discomfort Brief pinch during injection and occasional mild soreness for a few hours

[1] [7] Other notable effects include injection site reactions beyond pain (erythema, pruritus, induration in 13% of patients), increased heart rate (particularly with liraglutide), gallbladder disease (including gallstones and cholecystitis), and potential dehydration-related acute kidney injury